The Lynx Group
Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.
Read Article

The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma.
Read Article

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.
Read Article

Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Read Article

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.
Read Article

This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.
Read Article

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.
Read Article

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.
Read Article

Using FGFR Inhibitors in Clinical Practice
Dr Angela Lamarca discusses the use of FGFR inhibitors in daily practice. Their use will depend largely on data from currently ongoing second- and first-line clinical trials. She suggests that consideration should be given to their use in combination with chemotherapy and/or as maintenance therapy after first-line chemotherapy. Dr Milind Javle summarizes the field, suggesting that a time may come when patients with CCA are never treated with chemotherapy at all. Pemigatinib was FDA approved as second-line therapy in cholangiocarcinoma in May 2020.
Read Article

San Francisco, CA—Cholangiocarcinoma (CCA), a type of biliary tract cancer, is a rare malignancy, with no FDA-approved medications specifically for this type of cancer. The current standard first-line treatment for patients with locally advanced or metastatic CCA is a chemotherapy combination of gemcitabine and cisplatin.

Read Article

Page 3 of 5


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: